New Wegovy pill offers needle-free weight loss — but may not work for everyone

The first oral GLP-1 medicine for weight loss has been approved for usage successful nan U.S.

The Wegovy pill, from drugmaker Novo Nordisk, was cleared by nan Food and Drug Administration to trim excess assemblage weight, support semipermanent weight simplification and little nan consequence of awesome cardiovascular events.

Approval of nan once-daily 25mg semaglutide pill was based connected nan results of 2 objective tests — nan OASIS proceedings programme and nan SELECT trial.

WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS

The Wegovy pill demonstrated a mean weight nonaccomplishment of 16.6% successful nan OASIS 4 proceedings among adults who were obese aliases overweight and had 1 aliases much comorbidities (other aesculapian conditions), according to a property release. In nan aforesaid trial, 1 successful 3 participants knowledgeable 20% aliases greater weight loss.

The first oral GLP-1 medicine for weight nonaccomplishment has been approved for usage successful nan U.S. (iStock)

Novo Nordisk reported that nan weight nonaccomplishment achieved pinch nan pill is akin to that of injectable Wegovy and has a akin information profile.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS' LIVES, RESEARCHERS PROJECT

"With today's support of nan Wegovy pill, patients will person a convenient, once-daily pill that tin thief them suffer arsenic overmuch weight arsenic nan original Wegovy injection," said Mike Doustdar, president and CEO of Novo Nordisk, successful nan property release.

Novo Nordisk reported that nan weight nonaccomplishment achieved pinch nan pill is akin to that of injectable Wegovy and has a akin information profile. (James Manning/PA Images via Getty Images)

"As nan first oral GLP-1 curen for group surviving pinch overweight aliases obesity, nan Wegovy pill provides patients pinch a new, convenient curen action that tin thief patients commencement aliases proceed their weight-loss journey."

POPULAR WEIGHT-LOSS DRUGS COULD TAKE THE EDGE OFF YOUR ALCOHOL BUZZ, STUDY FINDS

The oral GLP-1 is expected to motorboat successful nan U.S. successful early January 2026. Novo Nordisk has besides submitted oral semaglutide for obesity to nan European Medicines Agency (EMA) and different regulatory authorities.

"Most broadside effects will beryllium GI-related and should beryllium akin to nan injectable, specified arsenic nausea, vomiting and constipation," an master said. (iStock)

Dr. Sue Decotiis, a aesculapian weight-loss expert successful New York City, confirmed successful an question and reply pinch Fox News Digital that studies show oral Wegovy is comparable to nan play injectable, conscionable without nan needles.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Although nan pill whitethorn consequence successful amended compliance and easiness of use, Decotiis warned that immoderate patients whitethorn not sorb nan medicine done nan gastrointestinal tract arsenic good arsenic pinch nan injectable type owed to individual idiosyncrasies successful nan body.

"Most broadside effects will beryllium GI-related and should beryllium akin to nan injectable, specified arsenic nausea, vomiting and constipation," she said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"In my practice, I person recovered tirzepatide (Mounjaro and Zepbound) to output much weight nonaccomplishment and fat loss than semaglutide by astir 20%," nan expert added. "This has been shown successful studies, often [with] less broadside effects."

More oral GLP-1s whitethorn beryllium coming successful 2026, according to Decotiis, including an Orforglipron exertion by Lilly and a caller operation Novo Nordisk drug, which is pending support later adjacent year.

One master warned that immoderate patients whitethorn not sorb nan medicine done nan gastrointestinal tract arsenic good arsenic pinch nan injectable version. (iStock)

"There will beryllium much caller narcotics disposable successful nan early that will beryllium much effective for patients who are much insulin-resistant and person not responded arsenic good to semaglutide and/or tirzepatide," nan expert said. "This is awesome news, arsenic caller narcotics affecting much receptors mean amended long-term results successful much patients."

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

As these medications go cheaper and easier to access, Decotiis emphasized that keeping up pinch patient manner habits — including due nutrition pinch capable protein and fiber, arsenic good arsenic accrued hydration — is basal to ensuring lasting results.

CLICK HERE FOR MORE HEALTH STORIES

"If not, patients will regain weight and could suffer musculus and not capable assemblage fat," she said.

Fox News Digital reached retired to Novo Nordisk for comment.